Heart failure & cardiomyopathiesRandomised controlled trial
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
- Design paper of a randomised controlled trial
- event-driven
- placebo-controlled
At least 1080 primary events expected; follow-up until at least 590 CV deaths
Authors' conclusion
VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational guideline-directed medical therapy, in a compensated ambulatory HF population.
Study context
- Population
- Patients with EF ≤40% without recent worsening heart failure (HF) on current foundational HFrEF therapyapprox
- Comparison
- Vericiguat vs placebo
- Primary endpoint
- Time to first hospitalization for heart failure (HHF) or CV death
Original publication
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial. Eur J Heart Fail. Published 30 October 2024. doi:10.1002/ejhf.3501
Summarised from the published abstract; every number is checked against it